A Randomized Study to Investigate the Efficacy and Safety of qw or q3w Trastuzumab, Paclitaxel and Carboplatin in Patients With IIB-IIIB HER2 Positive Breast Cancer.

Trial Profile

A Randomized Study to Investigate the Efficacy and Safety of qw or q3w Trastuzumab, Paclitaxel and Carboplatin in Patients With IIB-IIIB HER2 Positive Breast Cancer.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Trastuzumab (Primary) ; Carboplatin; Paclitaxel
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Acronyms PCH
  • Most Recent Events

    • 01 May 2013 Status changed from recruiting to active, no longer recruiting.
    • 01 May 2013 Primary endpoint 'Complete-pathological-response-rate' has been met.
    • 24 Mar 2012 Interim results presented at the 8th European Breast Cancer Conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top